secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2025-06-24T23:59:59+00:00
Accession:  0001367644-25-000153
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions secures $62.4M contract modification from ASPR for botulism antitoxin BAT
--------------------------------------------------------------------------------

- Modification and option exercise valued at $62.4 million under existing 10-year ASPR contract (75A50119C00075).
- BAT is used to treat symptomatic botulism from exposure to botulinum neurotoxin serotypes A through G.
- Supply supports U.S. government stockpile for military and civilian biodefense preparedness.
- Paul Williams, SVP, noted the award reinforces Emergent's role in public health countermeasures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764425000153/0001367644-25-000153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764425000153/ebs-20250623.htm
  HTML page:      https://secwatch.observer/filing/0001367644-25-000153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer